Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 24


Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.

Tibau A, López-Vilaró L, Pérez-Olabarria M, Vázquez T, Pons C, Gich I, Alonso C, Ojeda B, Ramón y Cajal T, Lerma E, Barnadas A, Escuin D.

Neoplasia. 2014 Oct 23;16(10):861-7. doi: 10.1016/j.neo.2014.08.012. eCollection 2014 Oct.


Treatment of HER2-positive breast cancer.

Figueroa-Magalhães MC, Jelovac D, Connolly RM, Wolff AC.

Breast. 2014 Apr;23(2):128-36. doi: 10.1016/j.breast.2013.11.011. Epub 2013 Dec 19. Review.


The growth factor receptor ERBB2 regulates mitochondrial activity on a signaling time scale.

Patel N, Barrientos A, Landgraf R.

J Biol Chem. 2013 Dec 6;288(49):35253-65. doi: 10.1074/jbc.M113.478271. Epub 2013 Oct 18.


From bench to bedside: lessons learned in translating preclinical studies in cancer drug development.

Lieu CH, Tan AC, Leong S, Diamond JR, Eckhardt SG.

J Natl Cancer Inst. 2013 Oct 2;105(19):1441-56. doi: 10.1093/jnci/djt209. Epub 2013 Sep 19. Review.


Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.

Gordon MA, Gundacker HM, Benedetti J, Macdonald JS, Baranda JC, Levin WJ, Blanke CD, Elatre W, Weng P, Zhou JY, Lenz HJ, Press MF.

Ann Oncol. 2013 Jul;24(7):1754-61. doi: 10.1093/annonc/mdt106. Epub 2013 Mar 22.


HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.

Sharma A, Koldovsky U, Xu S, Mick R, Roses R, Fitzpatrick E, Weinstein S, Nisenbaum H, Levine BL, Fox K, Zhang P, Koski G, Czerniecki BJ.

Cancer. 2012 Sep 1;118(17):4354-62. doi: 10.1002/cncr.26734. Epub 2012 Jan 17.


SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer.

Livingston RB, Barlow WE, Kash JJ, Albain KS, Gralow JR, Lew DL, Flaherty LE, Royce ME, Hortobagyi GN.

Breast Cancer Res Treat. 2011 Nov;130(1):123-31. doi: 10.1007/s10549-011-1698-5. Epub 2011 Aug 9.


Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.

Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, Villalobos IE, Eiermann W, Pienkowski T, Martin M, Robert N, Crown J, Bee V, Taupin H, Flom KJ, Tabah-Fisch I, Pauletti G, Lindsay MA, Riva A, Slamon DJ.

J Clin Oncol. 2011 Mar 1;29(7):859-67. doi: 10.1200/JCO.2009.27.5644. Epub 2010 Dec 28.


Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?

Bagnyukova TV, Serebriiskii IG, Zhou Y, Hopper-Borge EA, Golemis EA, Astsaturov I.

Cancer Biol Ther. 2010 Nov 1;10(9):839-53. Epub 2010 Nov 1. Review.


Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro.

Paik D, Cocco E, Bellone S, Casagrande F, Bellone M, Siegel EE, Richter CE, Schwartz PE, Rutherford TJ, Santin AD.

Gynecol Oncol. 2010 Oct;119(1):140-5. doi: 10.1016/j.ygyno.2010.06.024. Epub 2010 Jul 31.


Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro.

Cross SN, Cocco E, Bellone S, Anagnostou VK, Brower SL, Richter CE, Siegel ER, Schwartz PE, Rutherford TJ, Santin AD.

Am J Obstet Gynecol. 2010 Aug;203(2):162.e1-8. doi: 10.1016/j.ajog.2010.02.056. Epub 2010 Apr 24.


A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment.

Taube SE, Clark GM, Dancey JE, McShane LM, Sigman CC, Gutman SI.

J Natl Cancer Inst. 2009 Nov 4;101(21):1453-63. doi: 10.1093/jnci/djp334. Epub 2009 Oct 23.


The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study.

Wang L, Jiang Z, Sui M, Shen J, Xu C, Fan W.

BMC Cancer. 2009 Jul 11;9:226. doi: 10.1186/1471-2407-9-226.


Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients.

Barros-Silva JD, Leitão D, Afonso L, Vieira J, Dinis-Ribeiro M, Fragoso M, Bento MJ, Santos L, Ferreira P, Rêgo S, Brandão C, Carneiro F, Lopes C, Schmitt F, Teixeira MR.

Br J Cancer. 2009 Feb 10;100(3):487-93. doi: 10.1038/sj.bjc.6604885. Epub 2009 Jan 20.


Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342.

Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, Hayes DF, Winer EP, Dressler L.

Breast Cancer Res. 2006;8(6):R66.


HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells.

Wilson CA, Cajulis EE, Green JL, Olsen TM, Chung YA, Damore MA, Dering J, Calzone FJ, Slamon DJ.

Breast Cancer Res. 2005;7(6):R1058-79. Epub 2005 Nov 8.


Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.

Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, Luftner D, Ghani F.

Breast Cancer Res. 2005;7(4):R436-43. Epub 2005 Apr 8.


TP53 status determines clinical significance of ERBB2 expression in ovarian cancer.

Kupryjańczyk J, Madry R, Plisiecka-Hałasa J, Bar J, Kraszewska E, Ziółkowska I, Timorek A, Stelmachów J, Emerich J, Jedryka M, Płuzańska A, Rzepka-Górska I, Urbański K, Zieliński J, Markowska J.

Br J Cancer. 2004 Nov 29;91(11):1916-23.


Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients.

Ady N, Morat L, Fizazi K, Soria JC, Mathieu MC, Prapotnich D, Sabatier L, Chauveinc L.

Br J Cancer. 2004 Jan 26;90(2):443-8.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk